Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies

Osimertinib is a third-generation tyrosine kinase inhibitor that became the preferred first-line treatment option for metastatic non-small cell lung cancer with sensitizing epidermal growth factor receptor mutations. Drug-induced pneumonitis is known to occur with osimertinib. In case of severe pneu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bickert, Christiane, Kahnert, Kathrin, Kauffmann-Guerrero, Diego, Götschke, Jeremias, Syunyaeva, Zulfiya, Behr, Jürgen, Tufman, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202262/
https://www.ncbi.nlm.nih.gov/pubmed/34178120
http://dx.doi.org/10.1177/17588359211018028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202262/
https://www.ncbi.nlm.nih.gov/pubmed/34178120
http://dx.doi.org/10.1177/17588359211018028

Ejemplares similares